Brokerages forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will announce earnings of ($0.32) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Leap Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.28). Leap Therapeutics reported earnings per share of ($0.50) in the same quarter last year, which suggests a positive year over year growth rate of 36%. The firm is scheduled to announce its next quarterly earnings results on Monday, April 6th.
According to Zacks, analysts expect that Leap Therapeutics will report full year earnings of ($1.43) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.39). For the next year, analysts forecast that the firm will post earnings of ($1.09) per share, with EPS estimates ranging from ($1.71) to ($0.69). Zacks’ EPS averages are an average based on a survey of research analysts that cover Leap Therapeutics.
Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Thursday, November 14th. The company reported ($0.33) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.33).
Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its holdings in Leap Therapeutics by 63.3% in the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock worth $2,923,000 after purchasing an additional 606,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Leap Therapeutics by 183.4% during the 2nd quarter. Vanguard Group Inc. now owns 555,195 shares of the company’s stock valued at $994,000 after buying an additional 359,320 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Leap Therapeutics by 40.0% during the 2nd quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock valued at $61,000 after buying an additional 9,782 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Leap Therapeutics in the 3rd quarter worth about $28,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Leap Therapeutics in the 2nd quarter worth about $42,000. 15.61% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ LPTX opened at $0.82 on Friday. The stock’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.44. Leap Therapeutics has a twelve month low of $0.57 and a twelve month high of $3.55. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $19.31 million, a price-to-earnings ratio of -0.33 and a beta of 2.25.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Recommended Story: What is net income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.